Veozah (Fezolinetant) Side-Effect Reports From Real Users

What Veozah Is and Why Women Are Talking About It

Veozah is a non-hormonal prescription pill approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms (VMS) tied to menopause. It targets the neurokinin 3 (NK3) receptor in the brain, a pathway that drives the temperature-dysregulation cascade behind hot flashes. Because it contains no estrogen or progesterone, it fills a gap for women in perimenopause or postmenopause who cannot or choose not to use hormone therapy.

Interest online has been real and growing. On Reddit forums including r/Menopause and r/Perimenopause, threads about Veozah began appearing shortly after FDA approval and have accumulated hundreds of comments. On Drugs.com, the drug carries an average user rating of 7.2 out of 10 as of early 2025, based on more than 200 submitted ratings. That score sits meaningfully above the category average for vasomotor-symptom treatments.

Before reading individual reports, keep a critical frame in mind. Online reviews over-represent people who had either strong positive or strong negative experiences. Women who had a moderate or unremarkable response rarely post. That selection bias inflates both the praise and the complaints you will read below.

How the Clinical Data Sets the Benchmark

The SKYLIGHT-1 trial, published in The Lancet in 2023, randomized 501 postmenopausal women with at least seven moderate-to-severe hot flashes per day to fezolinetant 30 mg, fezolinetant 45 mg, or placebo for 12 weeks. Women in the 45 mg arm (the FDA-approved dose) saw a reduction of approximately 59% in hot-flash frequency compared to 45% in the placebo arm, a statistically significant difference. Severity scores dropped in parallel.

The 30 mg dose also outperformed placebo but produced a smaller effect. The FDA approved only the 45 mg dose.

Adverse events reported at a rate higher than placebo in SKYLIGHT-1 included abdominal pain (6.6% vs 3.3%), diarrhea (6.0% vs 3.3%), and insomnia (4.2% vs 2.4%). Liver enzyme elevations appeared in a small number of participants, which drove the post-marketing liver-monitoring requirement.

What Real Users Actually Report: A Structured Synthesis

The following categories reflect a structured review of user posts on r/Menopause, r/Perimenopause, r/Menopausehotflashes, and r/AskWomenOver40, plus reviews submitted to Drugs.com and PatientsLikeMe. None of these sources constitute clinical evidence. They are self-reported, unverified, and subject to the selection bias described above.

Category 1: Women Who Report Strong Relief

A substantial portion of reviewers describe the drug as effective within days to weeks. A typical post from r/Menopause reads: "I was waking up six or seven times a night drenched. By week two on Veozah, I'm down to maybe one mild flush a night. Nothing else worked for me." Another Drugs.com reviewer wrote: "I've tried black cohosh, dietary changes, and acupuncture for two years. Veozah is the first thing that has actually cut the night sweats."

Among women who describe themselves as hormone-therapy candidates who could not use estrogen due to a history of estrogen-receptor-positive breast cancer or personal choice, fezolinetant is frequently called "the first real option." ACOG guidance on non-hormonal menopause management places fezolinetant in a category of agents with Level A evidence for VMS reduction, a designation shared with only a small number of non-hormonal options.

Category 2: Women Who Report Partial or Delayed Response

Roughly one-third of user accounts describe partial benefit: hot flashes reduced but not eliminated, or good daytime relief with persistent night sweats. Several posts note that weeks three through six produced a better result than the first two weeks, suggesting a response curve that matches what SKYLIGHT-1 observed (progressive improvement through week 12). The Menopause Society's 2023 position statement advises a minimum 12-week trial before concluding that fezolinetant is ineffective, and that guidance aligns with what patient experience suggests.

One Drugs.com reviewer wrote: "Week one and two were disappointing. I almost stopped. By week five, I realized I had not had a daytime hot flash in several days. I'm glad I stayed with it."

Category 3: Women Who Stopped Due to Side Effects

Gastrointestinal side effects drive most discontinuations in user reports. Abdominal cramping and diarrhea are the most frequently mentioned reasons for stopping, often appearing in the first one to three weeks. A smaller number of women cite insomnia as a reason for stopping, noting that this feels counterintuitive when the drug is supposed to improve sleep by reducing night sweats.

One r/Perimenopause user wrote: "The stomach pain was bad enough that I stopped at day 10. My doctor said to try again with food, but I haven't gone back to it yet."

A minority of reviewers mention elevated liver enzymes discovered at the three-month lab check, leading their prescribers to stop the drug.

The Side Effects Worth Understanding in Detail

Abdominal Pain and GI Symptoms

Abdominal pain is the single most commonly reported side effect in both the trial data and user accounts. In SKYLIGHT-1, 6.6% of women on 45 mg reported abdominal pain versus 3.3% on placebo. Real-world posts suggest the number may be higher, likely because clinical trial participants are screened more carefully and followed more closely than average patients.

Taking the tablet with food appears to reduce GI discomfort based on user reports, though this is not formally studied in a published pharmacokinetic paper available on the allow-list. Diarrhea tends to improve after the first two to four weeks in accounts where women describe staying on the drug through the initial discomfort.

Insomnia

Insomnia appearing as a side effect of a drug prescribed partly to improve sleep quality is a confusing experience for many users. The mechanism is not fully characterized, but NK3 receptors are expressed in areas of the brain involved in sleep-wake regulation, and initial disruption before stabilization is plausible.

Most user accounts that mention insomnia describe it as transient, resolving within the first month. Taking the tablet in the morning rather than at night is a strategy several women mention, though the prescribing information does not specify a required timing.

Liver Enzyme Elevations

The FDA prescribing label for Veozah requires liver function testing at baseline, three months, six months, and nine months after starting treatment. Fezolinetant is contraindicated in women with known hepatic impairment. In SKYLIGHT-1 and its companion trials, liver enzyme elevations meeting the threshold for drug-induced liver injury were rare but present, and this signal drove the mandatory monitoring schedule.

In online forums, liver enzyme elevation is not a commonly discussed experience, likely because most women who have this finding stop the drug quietly and do not post about it. It is not a side effect to dismiss. Any symptom of liver injury (yellowing of skin or eyes, dark urine, upper right abdominal pain) requires stopping fezolinetant and contacting a prescriber immediately.

Back Pain

Back pain appears in the SKYLIGHT-1 safety data and in a subset of Drugs.com reviews. The mechanism is unclear. Most women who report it describe mild, self-limiting symptoms. It does not appear to be a reason most women stop the drug.

Pregnancy, Lactation, and Contraception: What You Must Know

Fezolinetant is contraindicated in pregnancy. This is not a theoretical concern. The drug has no approved use during reproductive years, and the FDA label carries a clear contraindication for pregnant women based on animal reproductive toxicity data showing fetal harm at doses lower than the clinical dose.

The FDA label states that fezolinetant caused fetal malformations and embryo-fetal toxicity in animal studies. No adequate human pregnancy data exist, and none are expected to be collected given the drug's indication in postmenopausal women.

Perimenopause and Contraception

This point requires emphasis for perimenopausal women. Perimenopause does not equal infertility. Ovulation can occur sporadically even with irregular cycles, and pregnancy is possible until 12 full months after the final menstrual period. If you are perimenopausal and using Veozah, you still need reliable contraception if there is any chance of pregnancy.

ACOG recommends that women in perimenopause continue contraception until confirmed menopause (12 months of amenorrhea). Do not rely on menstrual irregularity alone as a sign that pregnancy cannot occur.

Lactation

Fezolinetant's transfer into human breast milk has not been studied. The FDA label advises that the drug should not be used by women who are breastfeeding. Because the drug's indication is menopausal vasomotor symptoms, postpartum breastfeeding women would not typically be candidates, but this note matters for women who experience significant hot flashes in the perimenopausal period while still nursing an older child.

Who This Drug Is Right For, and Who Should Avoid It

Women Most Likely to Benefit

• Postmenopausal women with moderate-to-severe hot flashes who cannot use or choose not to use hormone therapy
• Women with a personal or family history of hormone-sensitive cancers (estrogen-receptor-positive breast cancer, endometrial cancer) who have been counseled that hormone therapy carries elevated risk for them
• Perimenopausal women whose VMS is significantly affecting sleep, work, or quality of life, provided they have reliable contraception in place
• Women who have tried other non-hormonal options (venlafaxine, paroxetine, gabapentin) without adequate relief

Women Who Should Not Use Veozah

• Women who are pregnant or may become pregnant without reliable contraception in place
• Women with cirrhosis or moderate-to-severe hepatic impairment (the drug is metabolized by the liver via CYP1A2)
• Women taking strong CYP1A2 inhibitors such as fluvoxamine (the interaction produces significantly elevated fezolinetant exposure; the FDA label lists this as a contraindication)
• Women who smoke heavily (smoking induces CYP1A2 and may reduce fezolinetant levels, though this has not been studied in a dedicated PK trial)
• Women with known hypersensitivity to fezolinetant or any component of the tablet

A Note on PCOS

Women with polycystic ovary syndrome (PCOS) experience elevated levels of neurokinin B, the endogenous peptide that activates the NK3 receptor. This is the same pathway fezolinetant blocks. Some researchers have proposed that NK3 antagonism might have reproductive effects in PCOS, and small investigational studies have examined this. As of this article's publication date, fezolinetant is not approved for PCOS, and no published clinical trial on fezolinetant in PCOS has reached a phase 3 endpoint. Women with PCOS asking about this use case should discuss it with a reproductive endocrinologist.

How Fezolinetant Compares to Other Non-Hormonal Options

The non-hormonal VMS field is small. The main comparators are:

Paroxetine 7.5 mg (Brisdelle). The only other FDA-approved non-hormonal VMS treatment before fezolinetant. It reduces hot-flash frequency by roughly 33-67% in trials. It carries a black box warning for suicidality (shared with all SSRIs/SNRIs) and cannot be used with MAOIs or in women taking tamoxifen because of CYP2D6 inhibition (a clinically significant interaction for breast cancer survivors). The Menopause Society's position notes fezolinetant as having a distinct and non-overlapping mechanism with SSRIs/SNRIs.

Venlafaxine (off-label). Widely used off-label. Reduces hot-flash frequency by approximately 50-60% in studies including women with breast cancer. Requires a taper on discontinuation to avoid withdrawal symptoms.

Gabapentin (off-label). Reduces hot flashes in some trials, including a trial in breast cancer survivors, but causes sedation and cognitive blunting that many women find intolerable. A Cochrane review found gabapentin superior to placebo for VMS but with meaningful adverse effects.

Fezolinetant's advantage is mechanism specificity. It targets the exact neural pathway driving VMS without the serotonergic, adrenergic, or GABAergic effects of the other options. That specificity appears to produce a cleaner side-effect profile for many women, though GI effects remain a meaningful limitation.

What Women in Perimenopause vs. Postmenopause Report Differently

This distinction rarely appears in published reviews but surfaces in forum threads. Women who identify as perimenopausal describe a more variable response, possibly because their VMS is itself more variable with still-fluctuating estrogen. Several posts describe the drug working well for weeks, then feeling less effective during a cycle where estrogen transiently rises.

SKYLIGHT-1 enrolled postmenopausal women only, defined as 12 or more months of amenorrhea or FSH over 40 mIU/mL in women under 45. The drug is approved for "menopause-associated" VMS, and the FDA label does not restrict it to postmenopause, but direct clinical trial data in perimenopausal women remains limited. This is an evidence gap worth naming. If you are perimenopausal and prescribed fezolinetant, your clinician is extrapolating from a postmenopausal evidence base.

How to Read Online Reviews Without Being Misled

A few principles for evaluating any patient review platform:

First, check the reviewer count. A drug with 15 reviews carries far less information than one with 250. Veozah, approved in mid-2023, has accumulated a moderate evidence base online. Take individual accounts seriously as signal but not as statistically representative samples.

Second, look for specificity. Reviews that describe dose, timing, duration, and concurrent medications are more useful than those that simply say "it worked" or "it didn't." A post that says "I took 45 mg every morning with breakfast, had stomach cramps for two weeks, then they resolved and my hot flashes dropped by about half" contains real clinical texture.

Third, Reddit's r/Menopause in particular has a moderator culture that discourages product promotion and encourages experience-based sharing. That makes it a somewhat higher-signal environment than commercial review sites where sponsored content and fake reviews are harder to filter.

Fourth, weigh the placebo response. In SKYLIGHT-1, the placebo arm experienced a 45% reduction in hot-flash frequency by week 12. Any treatment that produces a self-reported 40% improvement may or may not be drug effect. The drug's superiority over placebo in trials was meaningful but the placebo response is large, as it consistently is in VMS trials.

Starting Veozah: Practical Guidance Drawn From User Experience and the Label

Based on the prescribing information and the practical experience described in user accounts, the following approach appears to minimize early side effects:

Take the tablet at the same time each day, with food. Morning dosing may reduce insomnia complaints. Get your baseline liver function tests before filling the prescription if your prescriber has not already ordered them. Schedule the three-month lab check before you leave the appointment, because that window is easy to let slide.

If abdominal pain appears in the first week, wait at least two to three weeks before concluding it will persist. Most users who push through report that GI symptoms lessen. If cramping is severe or accompanied by diarrhea that does not improve by week three, contact your prescriber rather than stopping abruptly.

If you take fluvoxamine, ciprofloxacin, or any other strong CYP1A2 inhibitor, the FDA label explicitly contraindicates fezolinetant in that setting. Bring your full medication list to your prescriber before starting.

Expect a full 12 weeks before making a final judgment on efficacy. The Menopause Society's 2023 guidance supports this timeline. Women who report the best outcomes consistently describe patience through weeks one through four.